ABBV AbbVie Inc.
Company Analysis
Latest News
AbbVie Advances ELAHERE Toward Canadian Public Reimbursement
AbbVie has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for ELAHERE®, a treatment for adults with folate receptor-alpha...
AbbVie's Investigational Crohn's Drug ABBV-466 Shows Superiority in Mid-Stage Trial
AbbVie announced positive results from its Phase 2a study of ABBV-466. ABBV-466 is an investigational dual-targeting therapy for moderate to severe Crohn's...
AbbVie Presents Positive Long-Term Data for Key Immunology Drugs Skyrizi and Rinvoq
AbbVie announced the presentation of 20 new scientific abstracts at the 2026 United European Gastroenterology Week, highlighting positive long-term data for...
🔴 AbbVie is trading 4.3% down in after-hours trading
AbbVie is trading at $273.07, a -4.32% move in after-hours trading; the cause remains unconfirmed. - No confirmed October 16 company announcement has been...
🟢 AbbVie is trading 3.13% up — no confirmed catalyst
AbbVie is trading at $290.56, up +3.13%, with no confirmed company announcement explaining the October 15 move. - JPMorgan raised its price target to $300...
🟢 AbbVie is trading 3.05% up amid healthcare-sector strength
AbbVie is trading 3.05% up at $282.73 on October 14, 2026, amid healthcare-sector strength despite a weaker broader-market backdrop. - The healthcare sector is...
AbbVie Secures Scottish Backing for AQUIPTA as Shares Hit 52-Week High
On October 13, 2026, the Scottish Medicines Consortium (SMC) accepted AbbVie’s AQUIPTA (atogepant) for the acute treatment of migraine in eligible adults...
🟢 AbbVie is trading 3.05% up today after Phase 3 data showed 51% lower progression-or-death risk
AbbVie is trading 3.05% higher now at $274.83 after Phase 3 EPCORE DLBCL-2 data showed epcoritamab plus R-CHOP reduced the risk of disease progression or death...
AbbVie Secures Two FDA Breakthrough Therapy Designations for Cancer Drug
On October 7, 2026, AbbVie announced that the U.S. Food and Drug Administration (FDA) granted two Breakthrough Therapy Designations (BTDs) to its...
AbbVie updates third quarter 2026 guidance following a $216 million acquired R&D expense
AbbVie announced that its results for the third quarter 2026 will include a $216 million pre-tax charge related to acquired in-process research and development...
AbbVie Reports 51% Lower Progression Risk in Phase 3 Lymphoma Trial
AbbVie and partner Genmab announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial. The study evaluated epcoritamab plus standard R-CHOP...
AbbVie Advances Zumilokibart to Phase 3 After Positive Atopic Dermatitis Results
AbbVie reported positive results from a Phase 2 study of zumilokibart in adults with moderate to severe atopic dermatitis. The data were presented at the 2026...
AbbVie Expands AI Capabilities with Valkai Partnership and Receives Analyst Price Target Increase
AbbVie announced a new partnership with Valkai, a life sciences AI platform. The collaboration will enhance AbbVie's artificial intelligence capabilities...
AbbVie Wins First FDA Approval From Cerevel Deal for Parkinson’s Drug Juvmo
The FDA approved Juvmo (tavapadon), a once-daily oral treatment for adults with Parkinson’s disease. It can be used alone or alongside levodopa, a standard...
AbbVie-backed ADARx Pharmaceuticals raises $446 million in IPO
ADARx Pharmaceuticals, a biotech company backed by AbbVie, raised $446.3 million in its initial public offering. The company priced shares at $17 each. It saw...
AbbVie's EPKINLY wins Canada approval, cutting follicular lymphoma progression risk
Health Canada approved AbbVie’s EPKINLY (epcoritamab) for a new indication in treating follicular lymphoma (FL). The approval covers adult patients with...
AbbVie Secures Cantor Backing, New Eczema Drug Outperforms Rival Dupixent
Cantor Fitzgerald reiterated its Overweight rating on AbbVie shares. The firm cited positive clinical data for zumilokibart, an anti-IL-13 treatment for atopic...
AbbVie Atogepant Succeeds in Phase 3, Targeting Unmet Menstrual Migraine Need
AbbVie reported positive topline results from its Phase 3 LUNA study evaluating atogepant for the preventive treatment of menstrual migraine in adults. The...
🔴 AbbVie is trading 3% down today amid a broad healthcare-sector selloff
AbbVie is trading 3% down at $248.68 after healthcare stocks came under pressure on September 8, 2026; the XLV sector ETF fell 2.19% during regular trading. -...
BofA Securities Raises AbbVie Price Target Following Apogee Deal
BofA Securities increased its price target for AbbVie (ABBV) to $282 from $276, maintaining a Buy rating. This adjustment followed AbbVie's acquisition of...